Epitranscriptomics and epiproteomics in cancer drug resistance: therapeutic implications

Song，Huibin1; Liu，Dongcheng1; Dong，Shaowei1; Zeng，Leli2,3; Wu，Zhuoxun2; Zhao，Pan1; Zhang，Litu4; Chen，Zhe Sheng2; Zou，Chang1,5

2020-12-01

10.1038/s41392-020-00300-w

Signal Transduction and Targeted Therapy   影响因子和分区

2095-9907

2059-3635

Drug resistance is a major hurdle in cancer treatment and a key cause of poor prognosis. Epitranscriptomics and epiproteomics are crucial in cell proliferation, migration, invasion, and epithelial–mesenchymal transition. In recent years, epitranscriptomic and epiproteomic modification has been investigated on their roles in overcoming drug resistance. In this review article, we summarized the recent progress in overcoming cancer drug resistance in three novel aspects: (i) mRNA modification, which includes alternative splicing, A-to-I modification and mRNA methylation; (ii) noncoding RNAs modification, which involves miRNAs, lncRNAs, and circRNAs; and (iii) posttranslational modification on molecules encompasses drug inactivation/efflux, drug target modifications, DNA damage repair, cell death resistance, EMT, and metastasis. In addition, we discussed the therapeutic implications of targeting some classical chemotherapeutic drugs such as cisplatin, 5-fluorouridine, and gefitinib via these modifications. Taken together, this review highlights the importance of epitranscriptomic and epiproteomic modification in cancer drug resistance and provides new insights on potential therapeutic targets to reverse cancer drug resistance.

SCI

英语

第一 ; 通讯

Guangdong Basic and Applied Basic Research fund project[2019B1515120033] ; Science and Technology Foundation of Shenzhen[JCYJ20180305164128430] ; International Cooperation Foundation of Shenzhen[GJHZ20180928171602104] ; Shenzhen Economic and Information Committee "Innovation Chain and Industry Chain" integration special support plan project[20180225112449943]

Biochemistry & Molecular Biology ; Cell Biology

Biochemistry & Molecular Biology ; Cell Biology

WOS:000566974600001

NATURE PUBLISHING GROUP

2-s2.0-85090389346

Scopus

1.Shenzhen People’s Hospital (The Second Clinical Medical College,Jinan University; The First Affiliated Hospital,Southern University of Science and Technology),Shenzhen,518001,China
2.College of Pharmacy and Health Sciences,St. John’s University,Queens,11439,United States
3.Tomas Lindahl Nobel Laureate Laboratory,Research Centre,The Seventh Affiliated Hospital,Sun Yat-sen University,Shenzhen,518107,China
4.Department of Research,Affiliated Tumor Hospital of Guangxi Medical University,Nanning,530021,China
5.Shenzhen Public Service Platform on Tumor Precision Medicine and Molecular Diagnosis,Shenzhen,518001,China

Song，Huibin,Liu，Dongcheng,Dong，Shaowei,et al. Epitranscriptomics and epiproteomics in cancer drug resistance: therapeutic implications[J]. Signal Transduction and Targeted Therapy,2020,5(1).

Song，Huibin.,Liu，Dongcheng.,Dong，Shaowei.,Zeng，Leli.,Wu，Zhuoxun.,...&Zou，Chang.(2020).Epitranscriptomics and epiproteomics in cancer drug resistance: therapeutic implications.Signal Transduction and Targeted Therapy,5(1).

Song，Huibin,et al."Epitranscriptomics and epiproteomics in cancer drug resistance: therapeutic implications".Signal Transduction and Targeted Therapy 5.1(2020).